Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to…
Lilly and EVA Pharma partner to improve insulin access in Africa
Eli Lilly and Company (NYSE: LLY) and Egypt-headquartered EVA Pharma have developed a plan to collaborate to supply at least one million people in low- and middle-income countries. Many of the recipients of the vaccines will be in Africa. Roughly a month ago, Lilly’s share price fell about 4% after a fake Twitter account stated…